Epilepsy
📧 Sign up to get email alerts when something new happens for Epilepsy.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2023-05-22FDA Approved: LEVETIRACETAM — Supplemental Application (Major Pharmaceuticals)
FDA supplemental application approval for levetiracetam (Major Pharmaceuticals) under ANDA201157.
-
FDA approval · 2023-05-22FDA Approved: LEVETIRACETAM — Supplemental Application (Micro Labs Limited)
FDA approved a supplemental application for LEVETIRACETAM from Micro Labs Limited (ANDA211954).
-
FDA approval · 2023-05-19FDA Approved: LEVETIRACETAM SOLUTION — Supplemental Application (Chartwell RX, LLC)
The FDA approved a supplemental application for LEVETIRACETAM SOLUTION, adding a new solution dosage form of levetiracetam for Chartwell RX,…
-
FDA approval · 2023-05-19FDA Approved: LEVETIRACETAM — Supplemental Application (Amneal Pharmaceuticals LLC)
The FDA approved a supplemental application for levetiracetam from Amneal Pharmaceuticals LLC.
-
FDA label_change · 2023-05-19FDA Approved: LAMOTRIGINE — Supplemental Application (Actavis Pharma, Inc.)
The FDA approved a supplemental application for lamotrigine submitted by Actavis Pharma, Inc. The action pertains to updating or amending th…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2023-05-17FDA Approved: BRIVIACT — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for Briviact (brivaracetam) from UCB, Inc., updating the labeling following regulatory review.
-
FDA approval · 2023-05-17FDA Approved: BRIVIACT — Supplemental Application (UCB, Inc.)
The FDA approved a supplemental application for Briviact (brivaracetam) submitted by UCB, Inc., marking an approved modification to the exis…
-
FDA approval · 2023-05-17FDA Approved: LEVETIRACETAM — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental application for levetiracetam from Fresenius Kabi USA, LLC. The approval covers a change to an already approved …
-
CLINICAL_TRIALS trial_result · 2023-05-15Clinical Trial Update: Safety, Tolerability, and Exploratory Efficacy of Adjunctive EQU-001 for Seizures in Adults With Epilepsy [Phase 2]
Phase 2 trial update reporting safety, tolerability, and exploratory efficacy of adjunctive EQU-001 for seizures in adults with epilepsy.
-
CLINICAL_TRIALS trial_result · 2023-05-09Clinical Trial Update: Electrical Neuromodulation for Focal Epilepsy [Phase 1, Phase 2]
An update on an electrical neuromodulation trial for epilepsy spanning Phase 1 and Phase 2 stages; current status is unknown.
-
FDA approval · 2023-05-08FDA Approved: PHENYTOIN INFATABS — Supplemental Application (Prasco Laboratories)
FDA approved a supplemental application for Phenytoin Infatabs (phenytoin) from Prasco Laboratories. The approval updates the marketing auth…
-
FDA approval · 2023-05-04FDA Approved: TOPIRAMATE — Original Application (Endo USA, Inc.)
FDA approves Endo USA, Inc.'s original application for a generic Topiramate. Topiramate is used for epilepsy and migraine prophylaxis.
-
FDA approval · 2023-05-03FDA Approved: TOPAMAX — Supplemental Application (Janssen Pharmaceuticals, Inc.)
FDA approved Janssen's supplemental application for Topamax (topiramate) and updated the product labeling.
-
FDA approval · 2023-05-01FDA Approved: CLOBAZAM — Supplemental Application (Camber Pharmaceuticals, Inc.)
The FDA approved a supplemental application for CLOBAZAM (clobazam) submitted by Camber Pharmaceuticals, Inc. This action represents regulat…
-
FDA approval · 2023-05-01FDA Approved: CLOBAZAM — Supplemental Application (Bionpharma Inc.)
FDA approved a supplemental application for CLOBAZAM (clobazam) from Bionpharma Inc., under ANDA208819.
-
FDA approval · 2023-05-01FDA Approved: METHSUXIMIDE — Original Application (ANI Pharmaceuticals, Inc.)
The FDA approved ANI Pharmaceuticals' original application for methsuximide, a generic anticonvulsant used to treat absence seizures.
-
FDA approval · 2023-04-28FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for VIMPAT (lacosamide) submitted by UCB, Inc., finalizing the regulatory action on the product.
-
FDA approval · 2023-04-26FDA Approved: CLOBAZAM — Supplemental Application (Aurobindo Pharma Limited)
FDA approves a supplemental application for CLOBAZAM by Aurobindo Pharma Limited, updating the regulatory status of this clobazam product.
-
FDA approval · 2023-04-25FDA Approved: DIAZEPAM — Supplemental Application (Hospira, Inc.)
FDA approved Hospira's supplemental application for diazepam (generic) under ANDA 071583. This represents a supplemental approval for a gene…
-
CLINICAL_TRIALS trial_result · 2023-04-18Clinical Trial Update: Cannabidiol in Children and Young Adults With Rare Disease-associated Severe Epilepsy [Phase 2]
Phase 2 clinical trial update evaluating cannabidiol in children and young adults with rare disease-associated severe epilepsy.
-
FDA approval · 2023-03-31FDA Approved: PREGABALIN — Supplemental Application (ScieGen Pharmaceuticals, Inc)
The FDA approved a supplemental application from ScieGen Pharmaceuticals, Inc. for a generic pregabalin product. The approval covers the sam…
-
FDA approval · 2023-03-28FDA Approved: LACOSAMIDE — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental application for lacosamide submitted by Fresenius Kabi USA, LLC, updating the product's approval.
-
FDA approval · 2023-03-28FDA Approved: LACOSAMIDE ORAL SOLUTION — Supplemental Application (Ascend Laboratories, LLC)
The FDA approved a supplemental application to authorize lacosamide oral solution from Ascend Laboratories, expanding the product's dosage f…
-
FDA approval · 2023-03-24FDA Approved: CARBAMAZEPINE — Original Application (Ajanta Pharma USA Inc.)
FDA approved Ajanta Pharma USA's original ANDA for carbamazepine (generic anticonvulsant). This marks the availability of a generic carbamaz…
-
CLINICAL_TRIALS trial_result · 2023-03-21Clinical Trial Update: Low Frequency TMS for Depression in Epilepsy [NA]
Clinical trial update reporting completed study on low frequency transcranial magnetic stimulation for depression in epilepsy, with results …